Sunstone Capital and LU Bioscience invest 7 MSEK in Cantargia

Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia, announced earlier today that it has raised 7 MSEK. It is a joint investment by Sunstone Capital investing EUR 500,000 from its Early Engagement Program (EEP) and LUBio investing 3 MSEK.The company intends to use the capital infusion to further characterize its lead monoclonal antibody and prepare for GMP production and pre-clinical safety studies. Anki Malmborg Hager, acting CEO since February 2013, commented: “Through the capital injection we will have the opportunity to mobilize our